Fashions in drug usage change, just as they do in other topics. Sometimes the change may even have a logical basis-and the use of vasodilators for the treatment of heart failure is such an example.
First suggested in 1944 as a rational treatment for pulmonary oedema,' vasodilators had to wait for acceptable methods of bedside haemodynamic monitoring before their place in routine medical care could be defined accurately. Recent technical advances have, indeed, transformed our approach to the management of heart failure, which for so many years was dominated by digitalis. Chronic heart failure can now be managed by therapeutic manipulation ofthe venous circulation, the myocardial pump itself, or the arteriolar vasculature. This new physiological approach requires an understanding of the changes that occur in haemodynamics of heart failure. The cause of heart failure is usually diminished contractility of the left ventricle, owing either to direct myocardial damage (as in ischaemic heart disease) or to chronic pressure or volume overload (as in hypertension or valvular heart disease). An early response of the heart to decreased contractility is ventricular dilatation. In haemodynamic terms left ventricular dilatation is measured as an increase in left ventricular enddiastolic volume. This dilatation can be considered according to Starling's law as a compensatory mechanism to maintain stroke volume.
A second response of the failing circulation is a reflex increase in sympathetic tone and the production of angiotensin, which increases the heart rate, cardiac contractility, and peripheral vascular resistance-the last being an attempt to maintain arterial pressure to perfuse vital circulations such as those of the heart and brain. Both these compensatory mechanisms will eventually fail if the underlying disorder progresses. At first the failure will be clinically manifest only on exercise but later at rest as well.
What, then, are the advantages and drawbacks of the various approaches to the treatment of heart failure ? The remain a sheet anchor of treatment, because they enhance the excretion of sodium and water, thus decreasing ventricular preload. The other tool to modify the peripheral circulation is vasodilatation.
Appropriate drug treatment can dilate either the arteriolar or venous side of the circulation (or both). Vasodilators that relax the peripheral arteriolar bed will diminish the increased resistance against which the ventricle must empty, resulting in an increase in cardiac output. As a bonus, the improvement in pump performance produced by arteriolar vasodilators is accompanied by a reduction in myocardial oxygen consumption, since both systolic pressure and heart size are reduced.6 (In contrast, inotropic agents increase arterial pressure and the velocity of the shortening of the cardiac muscle fibres and tend to raise myocardial oxygen consumption.6) A hypothetical drawback of the use of an arteriolar vasodilator is that it might cause an unacceptable fall in arterial blood pressure. If left ventricular function were normal this might indeed happen, but the more abnormal the function of the left ventricle the greater the rise in stroke volume and cardiac output as the aortic impedance is reduced, thus lessening any unwanted fall in arterial pressure.7 Drugs that dilate the postcapillary venous capacitance beds cause a redistribution of intravascular blood volume from the central to the peripheral reservoirs-in other words, venous pooling. Again, the haemodynamic results differ in the normal and compromised heart. In normal circumstances venous pooling results in a diminution of stroke output and a compensatory rise in heart rate; but in heart failure diminution of venous return will reduce cardiac filling pressures and relieve the signs of raised pulmonary capillary pressure.7 Though the main sites of action of all vasodilators are on the peripheral circulation, they may also act to reduce segmental myocardial ischaemia, perhaps by increasing collateral blood flow.8 Furthermore, the compliance ofthe left ventricular musculature may be increased, though the underlying mechanism remains obscure.9
Vasodilators can be classified according to their principal peripheral vascular effects.7 Only those that may be given by mouth are of use in chronic heart failure. Nevertheless, several problems are associated with using vasodilators in heart failure. The patient must definitely be in heart failure before the drugs are given and an accurate profile of haemodynamic measurements should be established to choose the appropriate drug.7 Symptoms alone are notoriously unreliable, and the chest radiograph is of low diagnostic sensitivity. Some clinicians argue that detailed haemodynamic measurements are unnecessary, but they will admit to the value of using all available information from indwelling vascular catheters." In practice, the more deranged the haemodynamics the better seems the response to vasodilators, and patients with these features are more likely to have been intensively monitored.
Next, vasodilators have not been very successful in right heart failure, when the response is most unpredictable.'2 A third perplexing problem is the response to withdrawal of vasodilators: three patients treated with prazosin for heart failure showed appreciable deterioration in their clinical condition after drug withdrawal, but the effect has not been described with other vasodilators.'3 The final question, and probably the one of the greatest clinical importance, is whether vasodilators do maintain their effectiveness long term. The extent to which possible late decline in effectiveness is due to pharmacological tolerance to the drugs is debatable, but there is little good evidence that these agents prolong life, though the intolerable symptoms of heart failure may be remarkably improved in the short term. Enthusiasts'4 Histological studies have shown that the abnormal ectatic vessels of the portwine naevus are mostly confined to a 0-6 mm subepidermal zone' and so are within the laser destruction range, which extends to the upper 1 mm of dermis. Though the number of new vessels may triple after treatment the number of erythrocytes contained in these smaller vessels is much reduced; the result is that the lesion that formerly appeared purple becomes much pinker. ' Many patients, including some with other cutaneous vascular lesions, have now been treated.37 Recent studies
